IMUNON IDMC recommends continuing Phase 2 MRD study unchanged
IMUNON said its independent monitoring committee recommended its Phase 2 MRD study of IMNN-001 continue without changes after reviewing safety data, citing no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events.
IMUNON said an independent monitoring committee recommended its Phase 2 MRD study of IMNN-001 continue without changes after reviewing all safety data. The company said no cytokine release syndrome, systemic toxicities or serious immune-related adverse events were observed.